Mental health · Brain health · Longevity
Investing in the future of mental and brain health technology.
From prevention and early detection to treatment, recovery, resilience and longevity.
1B+people live with a mental health conditionWHO, 2025
Mental health · Brain health · Longevity
From prevention and early detection to treatment, recovery, resilience and longevity.
The platform
One mission, two independent paths. ALMA Ventures invests in companies building the future of mental and brain health. ALMA Foundation advances research and evidence for the entire field — open to every innovator.
Investing
Israel's first venture fund dedicated to mental and brain health. We back science-first companies and build them — from clinical validation to global scale.
Explore ALMA Ventures →Evidence
Advances research, implementation and data for the whole field — producing the clinical evidence that lets breakthrough technology move from the lab into care.
Explore ALMA Foundation →Each organization is independently governed and funded, and pursues the shared mission on its own terms.
ALMA Ventures
We invest in Israeli-linked, science-first companies that scale globally — and bring what capital alone cannot: clinical access, validation and a path to the payer.
First-look deal flow and clinical pilots through the ALMA network.
National-scale need compresses validation from years to months, de-risking each investment.
Clinical pilots, regulation, reimbursement and US go-to-market — alongside the capital.
Clinical outcomes agreed at investment and reported alongside the financials, every year.
ALMA Foundation
The Foundation supports the science and the first pilots that the market leaves unfunded — and turns every result into evidence the field can use.
Funds the clinical questions that come from hospitals and academia — with research partners in Israel and abroad.
Runs structured pilots inside real care settings — hospitals, health systems, community services.
Captures outcomes on validated scales and builds a shared data asset for the field.
Turns results into proof that clinicians, regulators and payers accept — shared openly, in Israel and worldwide.
Three levels of evidence
Efficacy on validated scales such as PHQ-9, GAD-7 and PCL-5.
Works in real settings: adoption, clinician capacity, time to first care.
Quality of life, people reached, lives improved.
Every solution must measurably improve real outcomes — proven in trials, not promised.
Private and public funding attracted for every philanthropic dollar, tracked and reported.
Israeli-validated protocols and tools adopted by health systems worldwide.
Fund a program, help hundreds.
Fund the system, reach millions.
Why now
The largest unmet need in healthcare is still diagnosed by observation. That is changing — and the change is investable.
Brain age from a single MRI. EEG built into headphones. The first FDA-cleared blood test for Alzheimer's.
FDA, May 2025The first randomized trial of an AI therapy chatbot cut depression symptoms by 51%.
NEJM AI, 2025GLP-1 drugs showed that millions will pay out of pocket to prevent disease, not only treat it.
45% of dementia cases are linked to modifiable factors, including depression and isolation. The same companies now serve all three.
Lancet Commission, 2024Why Israel
A nation of ten million under sustained pressure, with world-class science and hospital systems. Solutions are built, tested and deployed under real demand — then taken to the world.
“Israel didn't choose to be a living lab. Reality made it one.”Adi Ostry Matalon, Co-Founder · Ynet, 2026
TraumaTech
Israel has built more know-how in trauma, recovery and resilience than almost anywhere on earth. ALMA is helping turn it into a field.
Technologies for trauma, PTSD, chronic stress and recovery — from early detection to treatment.
Joint research, pilots and partnerships between Israeli innovators and health systems, universities and funders worldwide.
Bringing founders, clinicians, researchers and investors together across borders.
Where we invest
The convergence of mental health, brain health and longevity is creating a new category — and a new kind of company.
Digital biomarkers, cognitive screening and continuous monitoring.
Intake, triage and outcomes platforms that extend clinical capacity.
Software and clinician-plus-digital care built for reimbursement.
Stimulation, closed-loop systems and brain–computer interfaces.
Platforms for treatment-resistant care — including the delivery and monitoring platforms behind psychedelic-assisted therapy.
Our team
Venture exits, clinical leadership at Sheba and Columbia, and deep expertise in AI and neurotechnology. The team reflects the category it is building.
Co-Founder · Managing Partner
Investment strategist, 18+ years across finance, strategy and innovation. Former senior executive at international banks and impact funds; advisor to public bodies, health organisations and philanthropic foundations.
Co-Founder · Managing Partner
25+ years in VC leadership and venture creation. Exits include Playtika, Payoneer, Prolor and Orthospace. Chair, Wings IL · CEO, IMA Foundation.
Co-Founder · Investment Committee
Director, Integrated Rehabilitation Hospital, Sheba Medical Center. Founder & Chairman, MSR — Israel Center for Medical Simulation.
Venture Partner
Scientist-investor, PhD in behavioral neuroscience. Strategic leader, ScienceAbroad · former VP, AWZ Ventures · CSO, NEXVOX.
Principal · Head of US
Product leader, 10+ years in language and vision AI (Smartling, exit to Battery Ventures). Board member, Nazarian Family Foundation.
Psychiatry & Neuroscience
Founding Director, Sagol Brain Institute · Co-founder, GrayMatters Health · Head, Psychedelic Research Institute, TAU.
Psychiatry
Professor of Clinical Psychiatry, Columbia University / NYS Psychiatric Institute · Director, Mental Wellness Equity Center.
AI & Health
Director of Technology, Office of the CTO, Google, focused on mental health and PTSD · Former Chief Scientist of Israel.
Neurotechnology
Neuroscientist (PhD, Oxford; postdoc, Rockefeller). Director, Neurotechnology Division, MAFAT.
AI & Health
Professor, NYU (Computer Science) and NYU Langone (Precision Medicine) · formerly UnitedHealth / Optum.
Venture Building
Scaled 350+ startups. Former CEO, MassChallenge Israel · Co-founder, Moonscape Ventures.
Investors, families and foundations, clinical and public institutions — there is a way in for each. Let's talk.